# NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

* The new FDA voucher program aims to speed approval of drugs aligned with national health priorities.
* NRX-100, a preservative-free ketamine, is also under an Abbreviated New Drug Application (“ANDA”) with a priority review request.
* NRx has submitted full CMC data and draft labeling for NRX-100, meeting key Commissioner’s National Priority Voucher pre-qualification criteria.
* The company’s U.S.-based manufacturing aims to reduce foreign supply chain dependence and address diversion concerns.
* A patent on the preservative-free process and a citizen petition to withdraw preserved ketamine could bolster NRx’s market position.

 NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and PTSD, is accelerating its push toward regulatory approval of NRX-100, a preservative-free intravenous ketamine formulation. The company has filed an application under the newly created FDA Commissioner’s National Priority Voucher (“CNPV”) program, which promises significantly shortened review timelines for drugs that meet urgent U.S. health priorities (https://ibn.fm/VeYud).

 The new CNPV program, announced by FDA Commissioner Marty Makary on June 17, is intended to bring promising treatments to market more quickly. Makary had previously identified psychedelic drugs for treatment of suicidal depression and PTSD as a national priority. For eligible drugs, the program…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

 About PsychedelicNewsWire

 PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.PsychedelicNewsWire.com

 Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

 PsychedelicNewsWireSan Francisco, CAwww.PsychedelicNewsWire.com415.949.5050 OfficeEditor@PsychedelicNewsWire.com

 PsychedelicNewsWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/pnw/nrx-pharmaceuticals-inc-nasdaq-nrxp-applies-for-fda-commissioners-national-priority-voucher-for-iv-ketamine-nrx-100/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/nrx-pharmaceuticals-advances-nrx-100-with-fda-s-new-priority-voucher-program/b5e43820a9b57b6fa9b2881c6fbff862) 

 



[Reddit Post](https://www.reddit.com/r/PsychedelicsNews/comments/1lm1ues/nrx_pharmaceuticals_advances_nrx100_with_fdas_new/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/256/27/milkRMuG.webp)